相似文献
1
Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
Int J Nanomedicine. 2008;3(4):397-401. doi: 10.2147/ijn.s3259.
2
Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Expert Opin Pharmacother. 2008 Feb;9(2):301-9. doi: 10.1517/14656566.9.2.301.
3
Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Clin Transl Oncol. 2005 Jul;7(6):232-8. doi: 10.1007/BF02710168.
4
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13.
5
Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
Leuk Res. 2011 Jul;35(7):e128-30. doi: 10.1016/j.leukres.2011.03.023. Epub 2011 Apr 17.
6
Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
Prescrire Int. 2006 Feb;15(81):11-2.
7
New liposomal cytarabine formulation in CSF.
Clin Lab. 2010;56(1-2):69-70.
8
Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Ann Hematol. 2008 Dec;87(12):1009-12. doi: 10.1007/s00277-008-0546-0. Epub 2008 Aug 13.
9
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Int J Hematol. 2007 Jul;86(1):33-6. doi: 10.1532/IJH97.E0704.
10
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
J Neurooncol. 2007 Jan;81(2):201-8. doi: 10.1007/s11060-006-9218-x. Epub 2006 Aug 29.
引用本文的文献
1
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.
Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640.
2
Nanomedicinal products: a survey on specific toxicity and side effects.
Int J Nanomedicine. 2017 Aug 22;12:6107-6129. doi: 10.2147/IJN.S139687. eCollection 2017.
3
Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success.
Mar Drugs. 2014 Feb 17;12(2):1066-101. doi: 10.3390/md12021066.
4
Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.
Clin Investig (Lond). 2011 Oct;1(10):1391-1402. doi: 10.4155/cli.11.115.
5
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13.
6
Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma.
J Neurooncol. 2011 Jul;103(3):635-40. doi: 10.1007/s11060-010-0435-y. Epub 2010 Oct 17.
本文引用的文献
1
Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Leuk Lymphoma. 2014 Aug;55(8):1739-42. doi: 10.3109/10428194.2013.853765. Epub 2013 Nov 25.
2
Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Expert Opin Pharmacother. 2008 Feb;9(2):301-9. doi: 10.1517/14656566.9.2.301.
3
Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma.
Leuk Lymphoma. 2007 Sep;48(9):1849-51. doi: 10.1080/10428190701573232.
4
Toward optimal use of intrathecal liposomal cytarabine.
Leuk Lymphoma. 2007 Sep;48(9):1672-3. doi: 10.1080/10428190701573687.
5
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Eur J Clin Invest. 2007 Oct;37(10):808-13. doi: 10.1111/j.1365-2362.2007.01859.x. Epub 2007 Aug 28.
6
Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood. 2007 Sep 1;110(5):1698; author reply 1698-9. doi: 10.1182/blood-2007-02-073536.
7
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Int J Hematol. 2007 Jul;86(1):33-6. doi: 10.1532/IJH97.E0704.
8
CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.
Neurology. 2007 May 15;68(20):1674-9. doi: 10.1212/01.wnl.0000261909.28915.83.
9
Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
J Pediatr Hematol Oncol. 2007 Apr;29(4):222-6. doi: 10.1097/MPH.0b013e318041f112.
10
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood. 2007 Apr 15;109(8):3214-8. doi: 10.1182/blood-2006-08-043646. Epub 2007 Jan 5.
Zotero 插件